Highly purified eicosapentaenoic acid attenuates tissue damage in experimental myocardial infarction.
We examined the effects of dietary supplementation with eicosapentaenoic acid (EPA) on experimental myocardial infarction in dogs. Twenty-five dogs were fed standard diets, 10 of which were supplemented with EPA-ester (100 mg/kg body weight/day) for 8 weeks, while 15 served as controls. After ingesting EPA for 8 weeks, the ratio of EPA to arachidonic acid (AA) in platelet cell membranes significantly increased (from 0.033 to 0.105; p < 0.01). The chemotactic response of neutrophils to leukotriene B4 (LTB4) was reduced in the EPA group (34% reduction at 10(-6) M LTB4, p < 0.01). Also in the EPA group, the amount of 12-hydroxyeicosatetraenoic acid, one of the chemotactic products of AA in infarcted myocardium, was reduced to 40% (p < 0.05). EPA treatment resulted in significant reduction in the ultimate size of the infarcted area. Contractile function of infarcted myocardium was well-preserved in the EPA group. Myeloperoxidase activity, an indication of the infiltration of neutrophils into the infarcted myocardium, was less in the EPA group than in the controls (0.68 +/- 0.25 U/0.1 gr. vs 1.22 +/- 0.55 U/0.1 gr., p < 0.05). Therefore, we conclude that dietary supplementation with EPA attenuates ischemic myocardial damage through inhibition of neutrophilic infiltration into the infarcted myocardium.
Otsuji
S
S
Department of Cardiology and Pathology, Center for Adult Diseases, Osaka, Japan.
Shibata
N
N
Hirota
H
H
Akagami
H
H
Wada
A
A
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003402:Creatine Kinase / Q000187:drug effects; D004285:Dogs; D015118:Eicosapentaenoic Acid / Q000737:chemistry / Q000627:therapeutic use*; D005227:Fatty Acids / Q000097:blood; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009205:Myocarditis / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects; D009195:Peroxidase / Q000187:drug effects
D005227:Fatty Acids; D006893:Hydroxyeicosatetraenoic Acids; D015118:Eicosapentaenoic Acid; D009195:Peroxidase; D003402:Creatine Kinase